Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes

URN zum Zitieren dieses Dokuments:: urn:nbn:de:bvb:355-epub-377616
DOI zum Zitieren dieses Dokuments:: 10.5283/epub.37761

Mustroph, Julian ; Wagemann, Olivia ; Lücht, Charlotte M. ; Trum, Maximilian ; Hammer, Karin P. ; Sag, Can Martin ; Lebek, Simon ; Tarnowski, Daniel ; Reinders, Jörg ; Perbellini, Filippo ; Terracciano, Cesare ; Schmid, Christof ; Schopka, Simon ; Hilker, Michael ; Zausig, York ; Pabel, Steffen ; Sossalla, Samuel T. ; Schweda, Frank ; Maier, Lars S. ; Wagner, Stefan

Lizenz: Creative Commons Namensnennung 4.0 International
PDF
(1MB)

Veröffentlichungsdatum dieses Volltextes: 24 Sep 2018 15:02

Alternative Links zum Volltext:DOI Verlag Verlag

Details

Vorschau

Indiziert in

Bibliographische Daten exportieren

Zusammenfassung

Zusammenfassung

AimsThe EMPA-REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin. Overexpression and Ca2+-dependent activation of Ca2+/calmodulin-dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfunction and arrhythmias. We tested whether empagliflozin reduces CaMKII- activity and improves Ca2+-handling in human and murine ventricular myocytes. Methods and resultsMyocytes from wild-type mice, mice with transverse aortic constriction (TAC) as a model of HF, and human failing ventricular myocytes were exposed to empagliflozin (1mol/L) or vehicle. CaMKII activity was assessed by CaMKII-histone deacetylase pulldown assay. Ca2+ spark frequency (CaSpF) as a measure of sarcoplasmic reticulum (SR) Ca2+ leak was investigated by confocal microscopy. [Na+](i) was measured using Na+/Ca2+-exchanger (NCX) currents (whole-cell patch clamp). Compared with vehicle, 24h empagliflozin exposure of murine myocytes reduced CaMKII activity (1.60.7 vs. 4.2 +/- 0.9, P<0.05, n=10 mice), and also CaMKII-dependent ryanodine receptor phosphorylation (0.8 +/- 0.1 vs. 1.0 +/- 0.1, P<0.05, n=11 mice), with similar results upon TAC. In murine myocytes, empagliflozin reduced CaSpF (TAC: 1.7 +/- 0.3 vs. 2.5 +/- 0.4 1/100m(-1)s(-1), P<0.05, n=4 mice) but increased SR Ca2+ load and Ca2+ transient amplitude. Importantly, empagliflozin also significantly reduced CaSpF in human failing ventricular myocytes (1 +/- 0.2 vs. 3.3 +/- 0.9, P<0.05, n=4 patients), while Ca2+ transient amplitude was increased (F/F-0: 0.53 +/- 0.05 vs. 0.36 +/- 0.02, P<0.05, n=3 patients). In contrast, 30min exposure with empagliflozin did not affect CaMKII activity nor Ca2+-handling but significantly reduced [Na+](i). ConclusionsWe show for the first time that empagliflozin reduces CaMKII activity and CaMKII-dependent SR Ca2+ leak. Reduced Ca2+ leak and improved Ca2+ transients may contribute to the beneficial effects of empagliflozin in HF.

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Details

Vorschau

Indiziert in

Bibliographische Daten exportieren

Zusammenfassung

Zusammenfassung

Downloadstatistik

Downloads

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Universitätsbibliothek